![]() |
市場調查報告書
商品編碼
1305938
HPV 檢測和 PAP 檢測市場 - 按檢測類型、按技術(聚合酶鏈反應、液基細胞學、雜交捕獲、免疫診斷)、按最終用途及預測,2023 - 2032 年HPV Testing and PAP Test Market - By Test Type, By Technology, (Polymerase Chain Reaction, Liquid-based Cytology, Hybrid Capture, Immunodiagnostics), By End-use & forecast, 2023 - 2032 |
到2032年,全球HPV 檢測和PAP 檢測市場規模將大幅擴大。 HPV 和PAP 檢測領域的最新進展將為該行業帶來顯著的成長機會。圖像分析和人工智慧方面的進步推動了用於子宮頸抹片檢查解讀的電腦輔助系統的發展。這些系統可以幫助病理學家突出顯示異常細胞,提高篩查過程的準確性和效率。
全球人類乳突病毒檢測和子宮頸抹片檢測市場總體上按檢測項目、技術、最終用途和地區進行分類。
根據檢測方法的不同,從2023年到2032年,聯合檢測領域的行業佔有率將以超過16% 的年複合成長率成長。子宮頸癌和人類乳突病毒相關性傳播疾病發病率的上升增加了對聯合檢測的需求。根據美國癌症協會的資料,2023年,僅在美國就將診斷出約13,960 例新的侵襲性子宮頸癌病例。與單獨檢測子宮頸異常相比,聯合檢測具有更高的靈敏度。人類乳突病毒檢測和子宮頸抹片檢測相結合,可提高高級別癌前病變和早期子宮頸癌的檢測率。
根據技術的不同,聚合酶鏈反應(PCR)領域的產業價值將在2032年前取得豐厚的收益。 PCR 檢測的靈敏度和特異性高,可準確檢測和識別HPV DNA,有利於細分市場的成長。此外,PCR 檢測還能確定是否存在持續性HPV 感染,這種感染患子宮頸癌的風險較高。人們對早期檢測HPV 感染的認知不斷提高,這將進一步促進該細分市場的成長。
根據最終用途,到2032年,診斷中心細分市場的產值將大幅成長。由於這些機構擁有先進的技術和經濟有效的治療方法,越來越多的人傾向於選擇診斷實驗室,推動了該細分市場的成長。這些中心還能提供準確、早期的疾病診斷,增加了患者人數。診斷中心數量的激增將進一步為細分市場的成長創造有利的機會。
從地區角度來看,到2032年,亞太地區HPV 檢測和PAP 檢測市場規模將超過25 億美元。女性人口對子宮頸癌的易感性激增,增加了該地區對HPV 和PAP 檢測的需求。此外,該地區的擴張還可歸因於醫療基礎設施的不斷擴大,以及各種模式的有利監管環境。根據IBEF 預測,到2025年,印度醫療器械市場規模將達到500 億美元。
Global HPV Testing and PAP Test Market size will expand significantly through 2032. Recent advancements in HPV and PAP tests will create notable growth opportunities for the industry. Advances in image analysis and AI have led to the development of computer-assisted systems for Pap test interpretation. These systems can aid pathologists by highlighting abnormal cells, potentially improving the accuracy and efficiency of the screening process.
The overall global HPV testing and PAP test market is divided based on test, technology, end-use, and region.
Based on the test, industry share from the co-testing segment will grow at over 16% CAGR from 2023 to 2032. The rising prevalence of cervical cancer and HPV-related sexually transmitted diseases has increased the demand for co-testing. As per the American Cancer Society, in 2023, around 13,960 new invasive cervical cancer cases will be diagnosed in the U.S. alone. Co-testing provides higher sensitivity in detecting cervical abnormalities compared to either test alone. The combination of HPV testing and Pap testing improves the detection of high-grade precancerous lesions and early-stage cervical cancer.
Based on the technology, industry value from the polymerase chain reaction (PCR) segment will register lucrative gains through 2032. High sensitivity and specificity of PCR tests allow for the accurate detection and identification of HPV DNA, favoring segment growth. Moreover, PCR testing can identify the presence of persistent HPV infections, which are considered to have a higher risk of developing cervical cancer. Growing awareness about the early detection of HPV infection will further contribute to segment growth.
Based on the end use, industry value from the diagnostic centers segment will witness substantial gains through 2032. Growing preference towards diagnostic laboratories owing to the availability of advanced technologies and cost-effective treatment in these facilities is leading to segment growth. These centers also offer accurate and early disease diagnosis, which increases patient footfall. Surging number of diagnostic centers will further create lucrative opportunities for segment growth.
From the regional perspective, the Asia Pacific HPV testing and PAP test market size will reach over USD 2.5 billion by 2032. Surging female population base's susceptibility to cervical cancer has increased the need for HPV and PAP testing in the region. Moreover, regional expansion can also be attributed to expanding healthcare infrastructure, in line with favorable regulatory scenarios for modalities. As per IBEF, India's medical device market will reach USD 50 billion by 2025.